" class="no-js "lang="en-US"> ACELYRIN - Medtech Alert
Thursday, September 25, 2025
ACELYRIN | Pharmtech Focus

ACELYRIN

About ACELYRIN

ACELYRIN

ACELYRIN, INC. is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates and leveraging its expertise to rapidly advance these medicines to patients.

ACELYRIN is embedding a corporate culture of Courageous Caring™—placing patients first and embracing the concept that all of us are better than any one of us. ACELYRIN addresses the most basic human needs—to live a productive life free from diseases.

Related Story

ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases

November 16 2021

ACELYRIN, INC., an innovative clinical-stage biopharma company that identifies, acquires, and accelerates the development and […]